somagenics_logoSANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ – SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA.

There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression profiling and diagnostic purposes. There are many advantages to using NGS, including unlimited multiplexing, high sensitivity, sequence specificity and ability to detect miRNA sequence editing.  Targeted NGS brings these advantages to the quantification of any specific group of sequences of interest.  However, sequence bias in the construction of the small RNA libraries used in sequencing has so far limited the utility of NGS, both targeted and non-targeted. This bias gives distorted small RNA profiles and renders some species of RNA that might be good biomarkers unavailable for accurate quantification.

“RealSeq–T improves the accuracy and sensitivity of targeted NGS compared to current methods and provides accurate quantification of all miRNA species of interest,” said Dr. Brian Johnston, CEO of SomaGenics.  “We are excited [click to continue…]


Date: Tuesday Sept 30, 2014

LC SciencesIn the past, differential profiling and functional studies of microRNA (miRNA) has been performed mainly using tissues samples collected by invasive methods. However, in a clinical setting, more convenient and non-invasive methods are required, such as collection of peripheral blood or other bodily fluids. Recently, it has been demonstrated that miRNAs are present in circulating blood plasma, both free circulating and within exosomes, as well as within other biofluids such as cerebral spinal fluid, urine and even breast milk. These circulating miRNAs represent a potential new approach for diagnostic screening. [click to continue…]


Expands the Company’s Patent Portfolio in Oncology Therapeutics

Rosetta Genomics LogoPRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting microRNAs for the Treatment of Liver Cancer.”

This allowance is for a therapeutic patent that protects a method for treating hepatocellular carcinoma (HCC), or liver cancer, and covers the administration of a compound comprising a modified oligonucleotide that is an anti-miR-222. In addition, various modifications of the nucleotide are claimed. There is an additional claim which refers to the reduction of the levels of serum alpha-fetoprotein or serum des-gamma-carboxyprothrombin in the subject to be treated.

“HCC is the fifth most common cancer in the world and the third leading cause of cancer deaths. Because standard chemotherapy usually has no beneficial outcome on HCC patients, there is significant need for new therapeutic modalities and novel therapeutic [click to continue…]


EpimiRNA Consortium LogoSeptember 18, 2013 / B3C newswire / - Major new funding for research into epilepsy is announced today. The EpimiRNA Consortium, involving 16 partners from 8 European countries, the USA and Brazil has received €11.5 million funding from the European Union’s Framework Programme 7 to investigate molecular mechanisms, diagnostics and treatments for epilepsy.

Over 50 million people across the world suffer from epilepsy, making it the most common serious neurological disorder for which there is no cure. The causes for epilepsy are insufficiently understood with currently available treatments being sub-optimal and with a significant proportion of patients not responding. Recent discoveries have identified a new type of molecule in cells called microRNA which may be critical to controlling the changes in brain chemistry that accompany the development and course of epilepsy. The EpimiRNA Consortium represents a major interdisciplinary effort between epilepsy researchers, geneticists, clinicians, experts in advanced molecular sciences and research-active companies working together to understand molecular mechanisms, diagnostics and developing novel microRNA-based therapeutics to prevent the development of epilepsy, the occurrence of seizures or reverse epilepsy once established.

Prof. David Henshall, Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Coordinator of the EpimiRNA consortium comments: “Improved understanding of the causes of epilepsy is critical to [click to continue…]


Product innovation and the development of high-qualitative assays are the need of the hour

LONDON, Sept. 4, 2013 /PRNewswire/ — Rapid growth in microRNA (miRNA) research over the past two years, owing to its diagnostic and therapeutic potential, has fueled development in the global miRNA tools and services market. Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays and functional tools, qRT PCR remains the fastest-growing, while microarray is gradually being replaced by next-generation sequencing platforms.

New analysis from Frost & Sullivan (http://www.frost.com/prod/servlet/svcg.pag/HCLS), Global Analysis of MicroRNA Tools and Services Market, finds that the tools side of the market earned revenues of $110.0 million in 2012 and estimates this to more than double to reach $247.7 million in 2017. The US contributed to about 47% of the revenue followed by 36.7% from Europe, while leaving the rest to APAC and ROW. The miRNA services market earned revenues of $35.1 million in 2012 and this is expected to grow to $63.3 million in 2017. The end users covered are academic and research institutes, core facilities, and pharmaceutical and biotech companies.

The growth of therapeutic and diagnostic enterprises, higher research funding and increased outsourcing to contract research organizations in the US will present immense opportunities for the miRNA tools and services market. At the same time, [click to continue…]


Call for Papers

April 16, 2013

Call for papers for an open special issue on small/microRNAs: Small RNAs: Revolutionizing the Genomics Landscape The editors invite researchers to contribute original research articles as well as review articles focused on the use, development, or the application of genomics tools for investigating the role of small RNAs at the whole-genome level. The editors will […]

Read the full article →

Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 AACR Anual Meeting

April 8, 2013

NEW YORK, April 8, 2013 /PRNewswire/ – Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.  The abstract is titled “Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma […]

Read the full article →

Invitation to contribute with a book chapter on methods related to microRNAs and long non-coding RNAs for a book on “Structural and Functional RNA Mapping”

March 25, 2013

Dr. Lucrecia Alvarez is currently editing one of the Springer Book Series on Methods in Molecular Biology entitled “Structural and Functional RNA Mapping” and is looking for contributions: “All I am asking the authors to do is to present their routinely laboratory protocols in a define format and, therefore, there is not too much work […]

Read the full article →

Rosetta Genomics Receives 25th U.S. Patent Allowance

March 18, 2013

Award Strengthens Growing Portfolio of microRNAs in Viral Infection PHILADELPHIA and REHOVOT, Israel, March 18, 2013 /PRNewswire/ – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent Office related to U.S. Patent Application No. 12/517,760 entitled “Nucleic Acids Involved in […]

Read the full article →

Signature MicroRNA Expression Patterns Identified in Humans with 22q11.2 Deletion/DiGeorge Syndrome

February 26, 2013

Researchers at the University of Texas Southwestern Medical Center and Baylor Institute for Immunology Research have identified a novel expression signature in patients with DiGeorge Syndrome. DiGeorge Syndrome occurs because of a chromosomal deletion in 22q11.2, resulting in the hemizygous deletion of > 60 genes and 4 microRNAs. Peripheral blood taken from 31 DiGeorge Syndrome […]

Read the full article →